Pink Sheet
Scrip
Medtech Insight
HBW Insight
Generics Bulletin
In Vivo
Spotlight
GLP-1s
Interviews
FDA
Strategy
Generics
Biosimilars
Value Added Medicines
Business
Deals
Earnings
Manufacturing
Policy & Regulation
Regulatory Landscape
Drug Pricing
IP & Litigation
Tools & Trackers
What's Next?
Who's Hired?
UK Pricing Tracker
Company Rankings
Podcasts
Conference Coverage
Partner Insights
Generics Bulletin Perspectives
Exploring market-shifting topics for the off-patent sector.
View
In Vivo
Generics Bulletin
HBW Insight
Medtech Insight
Pink Sheet
Scrip
US Tecfidera Sales Could Plunge By $2.8bn In 2021
Market Reacts To Mylan ‘At-Risk’ Launch
Aug 21 2020
•
By
Dean Rudge
Tecfidera revenues will greatly diminish if Mylan and other generics flood the market • Source: Shutterstock
More from Earnings
More from Business